What are the mechanisms of primary and acquired resistance to TKI? Mechanisms of resistance in KIT-mutant melanomas are not fully understood, but likely involve secondary KIT mutations (as in GIST) or activation of downstream pathways like MAPK/PI3K regardless of KIT blockade [64]. Here, KIT is linked to gastrointestinal stromal tumor.